Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
seribantumab + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Concentra Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
**Seribantumab + paclitaxel** is a combination therapy under investigation primarily for **platinum-resistant or -refractory ovarian cancer**. Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that targets human epidermal growth factor receptor 3 (HER3/ErbB3), blocking the interaction with its ligand heregulin (HRG/NRG1), and thereby inhibiting downstream HRG-mediated ErbB3 signaling and inducing receptor downregulation. Paclitaxel is a standard chemotherapeutic agent that promotes microtubule stabilization, inhibiting cell division. The combination was studied in a phase II randomized clinical trial versus paclitaxel alone. While the overall unselected patient population showed no improvement in progression-free survival or overall survival, biomarker analyses suggested that patients with tumors expressing high HRG and low HER2 benefited from the addition of seribantumab. The drug combination has not received regulatory approval for any indication[1][3][6][7].
- Other names
- seribantumab and paclitaxel
02
Targets
ERBB3 (Erb-b2 receptor tyrosine kinase 3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on seribantumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on seribantumab + paclitaxel.